** Shares of transdermal pharma products maker Nutriband
rise ~28% to $6.67
** Brokerage Noble Capital starts coverage on NTRB with "outperform" rating and sets PT at $13
** PT represents a 148% upside to the stock's last
** NTRB is developing Aversa, a proprietary technology that makes transdermal patches safer by preventing abuse and misuse of potent opioids like fentanyl
** Brokerage says NTRB's tech has "abuse-deterrent" features that differentiate it from other transdermal patches on the market
** Also notes NTRB's partnership to add the Aversa technology to Kindeva's transdermal fentanyl patch could be a highly effective means to stop misuse
** NTRB shares doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。